Melanotan 2: Tanning Peptide, Real Risks, No Approval

At a Glance

Melanotan 2 is the peptide dermatologists tend to hear about after the fact: a patient arrives with a sudden crop of dark moles, or an emergency department sees a young man with an erection that will not settle. It was designed in Tucson in the 1990s as a way to tan without ultraviolet damage. Small pilot studies showed it does tan people and, unexpectedly, causes erections. The sexual-function line was developed further into bremelanotide (PT-141), now an approved drug for low desire in women. Melanotan 2 itself went no further and has lived on the internet ever since, sold as a research chemical and nicknamed the “Barbie drug”.

My verdict up front: Melanotan 2 works as a tanning agent, and that is the problem. It acts on pigment cells everywhere, including in moles, and on brain receptors that control nausea, appetite and sexual arousal. The human safety data for repeated use consist of case reports, and those case reports are not reassuring.

How it works

Alpha-melanocyte-stimulating hormone (alpha-MSH) is cut from the pro-opiomelanocortin precursor and binds a family of five melanocortin receptors. On melanocytes, MC1R activation shifts pigment production from reddish pheomelanin toward brown-black eumelanin. That is the tan.

Melanotan 2 is a shortened, ring-closed version of alpha-MSH that resists breakdown and binds strongly to several of these receptors at once. MC1R explains the pigmentation. MC4R and MC3R in the hypothalamus and spinal cord explain the rest: spontaneous erections and higher sexual desire, reduced appetite, nausea, and the odd stretching-and-yawning complex seen in the first human study [1].

Because the drug stimulates melanocytes without UV damage, people hoped it might even protect against skin cancer. That hypothesis was never tested. What dermatologists have documented instead is that existing moles darken, new ones appear, and some lesions turn out to be dysplastic or malignant [6–9].

What the evidence shows

Human studies

That is the entire controlled human literature: 23 men, single doses or two-week courses. Nobody has studied repeated use over months, which is how the product is actually used.

Case reports and user studies

The real-world picture comes from what doctors report:

• Eruptive and changing moles after injection [6][7], in one report within 24 hours of a single dose [7].
• Melanoma or melanoma in situ in users, mostly combined with sunbed use [8][9]. A 2017 review of alpha-MSH analogue misuse concluded that this case-report signal, plus unknown product content, makes unregulated use risky [10].
• Priapism needing aspiration, phenylephrine or surgical decompression [11][12].
• A sympathomimetic toxidrome with rhabdomyolysis and kidney injury after a 6 mg injection [13], and a renal infarction attributed to the drug [14].

Two studies looked at users themselves. An analysis of 623 forum posts from 205 people in the UK and Ireland found that use clustered around sun holidays and bodybuilding competitions, often with sunbeds, alongside misinformation and contaminated-product risks [15]. An anonymous survey of forum users asked about motivation, hesitation, how hard it was to buy and plans to keep using; its authors note that melanotan can be bought online with relative ease [16]. In England and Wales, needle and syringe programmes were already being asked for melanotan advice in 2008 [5].

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

How these protocols are used in practice:

• Titration is the norm. Nausea and erections are dose-dependent and strongest in the first days, so community advice is to start at 50–250 mcg. Users who jumped to 1 mg daily describe persistent nausea and erections, and other users advise staying at or below 0.5 mg daily (thread).
• Most users combine it with sun or sunbeds, because the tan develops faster with UV. This combination is exactly what appears in the melanoma case reports.
• Bedtime dosing and an antihistamine before the dose are the commonly reported ways to sleep through nausea and flushing.
• The trial doses were weight-based and given for two weeks at most. Practice doses sit in the same milligram range, but the duration (months, often several seasons in a row) has no trial behind it.

For injection technique, sterility and reconstitution basics, see the peptide injection guide.

What people report: what works and what doesn’t

Reported to work

• Tanning. Freckles and existing moles darken first, usually within about a week, and users take this as a sign the product is genuine. Overall skin tone follows in roughly 3 days to 3 weeks at 0.25–0.5 mg daily, faster with UV (r/Melanotan2, r/Melanotan2).
• Appetite suppression, reported most often with nasal use.
• Libido and erections, which some users want and many do not.

Mixed or unclear

• How long the tan lasts after stopping; most users keep dosing weekly.
• Nasal sprays: the dose per spray depends on how the bottle was mixed, and Australian regulators found bottles labelled 30 mg that contained 22–54 mg [19].
• Shade: some report “not as dark as hoped”, often at 250 mcg every other day.

Reported not to work, or disappointing

• No visible change at low intermittent doses, often blamed on underdosed or fake product. That is plausible: a laboratory analysis of vials sold as 10 mg found 4.3–8.8 mg plus 4–6 % unknown impurities [17].
• Side effects that make people stop: nausea within minutes, facial flushing, spontaneous or painful erections in the first days, irritability, and above all darkening or new moles (r/Melanotan2, forum analysis [15]).

What a proper trial would need to show: that repeated dosing across a full season tans people without increasing atypical moles or melanoma, measured with dermatologist-run total-body photography against a control group. No such trial exists.

Safety and side effects

Expected, dose-related effects from the trials [1–3]: nausea (sometimes severe), flushing, yawning and stretching, reduced appetite, drowsiness and fatigue, and spontaneous erections lasting hours.

Serious events from case reports:

• Pigmented lesions: eruptive nevi, darkening of existing nevi, dysplastic nevi, melanoma and melanoma in situ [6–9]. In a teenager with a hereditary melanoma syndrome (FAMMM), moles changed within weeks of daily injections plus sunbed use [18].
• Priapism, an emergency that can permanently damage erectile function if it is not treated within hours [11][12].
• Sympathomimetic toxicity and rhabdomyolysis [13]; renal infarction [14]. FDA’s safety review also cites posterior reversible encephalopathy syndrome (PRES) [20].

People for whom the risk is plainly unacceptable: anyone with a personal or family history of melanoma, many or atypical moles, a hereditary melanoma syndrome, a history of priapism or a condition that predisposes to it (such as sickle cell disease), pregnancy or breastfeeding, and uncontrolled blood pressure. Combining it with PDE5 inhibitors or PT-141 stacks erection-promoting drugs.

The quality problem is documented. Laboratory analysis of online vials [17] and regulator testing of nasal sprays [19] show that users do not know the dose or purity they inject, and shared equipment was a concern from the first public-health reports [5]. If you have used Melanotan 2, a baseline full-skin check by a dermatologist with photographic follow-up of your moles is a sensible next step.

Legal and regulatory status

• United States. Not approved. FDA’s page on bulk substances that may present significant safety risks (content current as of 22 April 2026) lists Melanotan II among nominations that were withdrawn, citing case reports of melanoma, PRES, sympathomimetic toxidrome and priapism [20]. It is not on the 503A bulks list.
• EU and Germany. No marketing authorisation; supply for human use is supply of an unauthorised medicinal product. The Danish Medicines Agency has warned against it since 2008 (warning), and Sweden’s Läkemedelsverket advises against all use (page).
• UK and Australia. The MHRA has issued warnings and closed websites. Australia’s TGA issued a safety advisory in August 2026 after testing seized nasal sprays, and a supplier paid 27 infringement notices [19].
• Sport. Not approved for human use anywhere, so it falls under WADA 2026 class S0 (non-approved substances), prohibited at all times [21].

How it fits: Melanotan 2 vs Melanotan 1 and PT-141

For pigmentation with a medical reason, afamelanotide is the tested molecule. For sexual function, PT-141 is. Melanotan 2 sits between them with the evidence of neither.

Related Articles

• Melanotan 1 (Afamelanotide): The Approved Tanning Peptide
• PT-141 (Bremelanotide): Evidence and Uses
• PT-141 Dosage Guide
• Peptide Injection Guide
• Peptide Sourcing: Quality and Grey-Market Risks
• Peptides and WADA Anti-Doping Rules